AI Article Synopsis
- The study aimed to improve treatment outcomes for congestive heart failure (CHF) patients recovering from a myocardial infarction (MI) by using a combination of magnesium and potassium salts of gluconic acid, eplerenone, and rivaroxaban.
- Researchers conducted the study with 84 CHF patients who had experienced a past MI at a cardiology center in Ukraine.
- The findings indicated that combining rivaroxaban with standard therapy significantly enhanced anti-ischemic effects, while eplerenone promoted notable recovery of the left heart muscle after the MI.
Article Abstract
Objective: The aim: To increase the treatment effectiveness of CHF patients after MI with stenting by using magnesium and potassium salts of gluconic acid, eplerenone, and rivaroxaban in complex therapy.
Patients And Methods: Materials and methods: The research was performed at the premises of Ivano-Frankivsk Regional Clinical Cardiology Centre, Ukraine. 84 patients with CHF after past MI were examined.
Results: Results and conclusions: A more pronounced anti-ischemic effect has been linked to the use of combination therapy with rivaroxaban on the background of basic therapy (BT) in patients with CHF after MI, compared with the use of magnesium and potassium salts of gluconic acid or eplerenone. The use of eplerenone in the complex treatment of these patients on the background of BT has been proven to provide a pronounced reverse remodeling of the left myocardium in the postinfarction period.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!